Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJUS.L Regulatory News (JUS)

  • There is currently no data for JUS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Kepler Trust Intelligence: Manager change analysis

9 Dec 2020 09:52

RNS Number : 0644I
Jupiter US Smaller Companies PLC
09 December 2020
 

Jupiter US Smaller Companies (JUS)

09/12/2020

 

Analysis of manager change from Kepler Trust Intelligence

The board of Jupiter US Smaller Companies (JUS) has awarded the management contract to the US small cap growth team at Brown Advisory. JUS's portfolio will be managed by Chris Berrier, who will take over in April 2021. This follows the announcement in October of the retirement of Robert Siddles of Jupiter, who has run JUS for 20 years.

Robert has had a long and distinguished career, but management is passing to a team which also has considerable experience and a solid track record. Brown Advisory has run its small cap growth strategy since the early 1990s, but its current form dates back to 2006 when Chris took over the portfolio management role. Chris brought more of a focus on downside protection and awareness of valuations to what is still fundamentally a quality growth strategy, and that has resulted in impressive absolute and risk-adjusted performance under his tenure. The Brown Advisory US Smaller Companies UCITs fund, which follows the same small cap growth strategy, has performed particularly strongly on the downside over the past five years, and has displayed a superior downside capture ratio, upside/downside capture ratio and Sharpe ratio to JUS and the other small cap US smaller companies investment trust over this period.

In a period of strong returns for growth stocks, it has also significantly outperformed its Russell 2000 Growth benchmark. Over the past ten years, the Brown Advisory US Smaller Companies UCITS fund has generated returns of 13.4% a year compared to 12.1% for the growth benchmark and just 9.4% for the Russell 2000 Index. Over the past five years the outperformance has been even higher, with annualised returns of 14.7% for the fund compared to 11.2% for the benchmark and 7.6% for the market.

Chris and the team will be running a much more explicitly growth-focussed strategy than the manager they take over from. When we met with Chris recently, he stressed that he and the team look for long-term compounders. This means companies which are market leaders or show the ability to rapidly gain market share, which have a differentiated business model that facilitates this, and which are in a large or growing market. High importance is placed on good quality, trustworthy management, with alignment of interests and incentives with shareholders. They expect these companies to show higher returns on invested capital than their peers, with incremental revenue gains from efficient use of capital or rising margins. However, Chris believes that valuation can be extremely important on a five to ten year view, and he is wary of not overpaying for the next big thing and creating excessive downside risks.

Kepler View

We believe the board of JUS have made a very interesting appointment which makes the trust an altogether different proposition. For those with a shorter-term perspective, or those seeking an entry point into US small caps, we think the double-digit discount could be an opportunity. While many stocks and funds with exposure to the US domestic economy or US small caps have rallied in recent weeks, JUS has not. In our view the appointment of a new manager could be a catalyst for a re-rating.

CLICK HERE TO READ THE FULL REPORT

 

Visit http://www.trustintelligence.co.uk/investor for more high quality independent investment trust research.

 

Important information

This report has been issued by Kepler Partners LLP. The analyst who has prepared this report is aware that Kepler Partners LLP has a relationship with the company covered in this report and/or a conflict of interest which may impair the objectivity of the research.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise and you may get back less than you invested when you decide to sell your investments. It is strongly recommended that if you are a private investor independent financial advice should be taken before making any investment or financial decision.

Kepler Partners is not authorised to make recommendations to retail clients. This report has been issued by Kepler Partners LLP, is based on factual information only, is solely for information purposes only and any views contained in it must not be construed as investment or tax advice or a recommendation to buy, sell or take any action in relation to any investment.

The information provided on this website is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Kepler Partners LLP to any registration requirement within such jurisdiction or country. In particular, this website is exclusively for non-US Persons. Persons who access this information are required to inform themselves and to comply with any such restrictions.

The information contained in this website is not intended to constitute, and should not be construed as, investment advice. No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. Any views and opinions, whilst given in good faith, are subject to change without notice.

This is not an official confirmation of terms and is not a recommendation, offer or solicitation to buy or sell or take any action in relation to any investment mentioned herein. Any prices or quotations contained herein are indicative only.

Kepler Partners LLP (including its partners, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, but will at all times be subject to restrictions imposed by the firm's internal rules. A copy of the firm's Conflict of Interest policy is available on request.

PLEASE SEE ALSO OUR TERMS AND CONDITIONS

Kepler Partners LLP is authorised and regulated by the Financial Conduct Authority (FRN 480590), registered in England and Wales at 9/10 Savile Row, London W1S 3PF with registered number OC334771.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRATLBLTMTAMMMM
Date   Source Headline
11th May 20216:03 pmRNSChange of Ticker
11th May 202112:59 pmRNSNet Asset Value(s)
11th May 20219:59 amRNSNet Asset Value(s)
10th May 202112:00 pmRNSChange of Name
10th May 202110:13 amRNSNet Asset Value(s)
7th May 202110:04 amRNSNet Asset Value(s)
6th May 20211:09 pmRNSResult of General Meeting
6th May 20219:44 amRNSNet Asset Value(s)
5th May 202110:07 amRNSNet Asset Value(s)
4th May 202110:53 amRNSNet Asset Value(s)
4th May 202110:12 amRNSNet Asset Value(s)
30th Apr 20216:00 pmRNSTotal Voting Rights
30th Apr 202110:54 amRNSNet Asset Value(s)
29th Apr 20219:51 amRNSNet Asset Value(s)
29th Apr 20217:00 amRNSKepler Trust Intelligence: New Research
28th Apr 202110:35 amRNSNet Asset Value(s)
27th Apr 20219:58 amRNSNet Asset Value(s)
26th Apr 202110:36 amRNSNet Asset Value(s)
23rd Apr 20219:53 amRNSNet Asset Value(s)
22nd Apr 202110:28 amRNSNet Asset Value(s)
21st Apr 202110:52 amRNSNet Asset Value(s)
20th Apr 202110:02 amRNSNet Asset Value(s)
19th Apr 202112:00 pmRNSPortfolio update after portfolio reorganisation
19th Apr 202110:01 amRNSNet Asset Value(s)
16th Apr 202112:00 pmRNSMonth end portfolio information
16th Apr 202111:04 amRNSNet Asset Value(s)
15th Apr 202110:04 amRNSNet Asset Value(s)
14th Apr 202110:37 amRNSNet Asset Value(s)
13th Apr 202110:06 amRNSNet Asset Value(s)
12th Apr 202110:46 amRNSNet Asset Value(s)
12th Apr 20217:00 amRNSCircular and notice of general meeting
9th Apr 202110:02 amRNSNet Asset Value(s)
8th Apr 202110:04 amRNSNet Asset Value(s)
7th Apr 202111:08 amRNSNet Asset Value(s)
6th Apr 202112:53 pmRNSNet Asset Value(s)
6th Apr 202112:22 pmRNSNet Asset Value(s)
1st Apr 202111:55 amRNSNet Asset Value(s)
1st Apr 20219:00 amRNSChange of advisers and registered office
31st Mar 20215:52 pmRNSTotal Voting Rights
31st Mar 20219:59 amRNSNet Asset Value(s)
30th Mar 202110:54 amRNSNet Asset Value(s)
29th Mar 20219:55 amRNSNet Asset Value(s)
26th Mar 202110:07 amRNSNet Asset Value(s)
25th Mar 202111:14 amRNSNet Asset Value(s)
24th Mar 202110:09 amRNSNet Asset Value(s)
23rd Mar 202110:48 amRNSNet Asset Value(s)
22nd Mar 202110:15 amRNSNet Asset Value(s)
19th Mar 202110:44 amRNSNet Asset Value(s)
18th Mar 202111:50 amRNSPortfolio Update
18th Mar 202110:16 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.